Seven drugs were removed from the Internet due to the transformation of production lines, rising costs and other reasons

[industry trends of China Pharmaceutical network] on March 6, Gansu public resources trading network issued the notice of "canceling the qualification of some drugs winning the bidding and networking" According to the notice, 7 drugs from 6 enterprises have been unable to guarantee the normal supply of medical institutions due to the transformation of production lines and rising costs These seven drugs include butorphanol tartrate nasal spray of Hengrui pharmaceutical, Zhupo powder of Baohetang pharmaceutical, and Ankahuangmin capsule of Lanzhou foci pharmaceutical Among them, butorphanol tartrate nasal spray (specification) produced by Shanghai Hengrui Pharmaceutical Co., Ltd 10mg / ml), which belongs to class II psychotropic drugs, can be purchased offline by all medical institutions; Xiaoer Zhupo powder (formerly known as Zhupo Houzao powder, 0.3g * 10 bottles) produced by Baohetang Pharmaceutical Co., Ltd has no online transaction record since it was put on the Internet, please select similar alternative products or purchase according to other compliance channels by the required medical institutions; the other three abandoned drugs of the same specification have been accepted by other enterprises, which can guarantee normal supply Should   It is understood that, in addition to the production line transformation, production suspension and cost increase, pharmaceutical enterprises actively apply for the cancellation of drug network Under the control of the bidding policy and the influence of the hospital's second price negotiation, their products are facing price drop in multiple regional markets Some regions implement the national low price linkage In order to keep the market price and earn profits, enterprises have to give up some Regional market In addition to Gansu Province, Hainan, Shaanxi, Ningxia, Inner Mongolia and other places have also issued the notice of canceling the qualification of some drugs to be put on the Internet since this year, including winning the bid and trading drugs In February, Shaanxi public resources Trading Center released the announcement on the adjustment of drug information for some online transactions Among them, 10 drugs were suspended or directly withdrawn from the network due to non-compliance with the regulations, 2 of them were suspended from the network due to ornidazole sodium chloride injection, and 8 of them were withdrawn from the network On January 22, Ningxia pharmaceutical centralized purchase network issued the notice on canceling the qualification of winning the bid (hanging the net) for 48 drugs of erdosten capsule and other products, and the enterprise applied for canceling 48 drugs of hanging the net Among them, 23 drugs are not bidding temporarily, 20 drugs are low-cost, and 1 drug is directly on the Internet In addition, according to different categories, it is divided into 19 proprietary Chinese medicines and 26 chemicals On January 3, Hainan public resources trading center issued the notice of Hainan Province on publicizing the treatment results of price reduction of anticancer drugs in 2019 A total of 17 drugs lost the qualification of Internet access due to inadequate price reduction or unwillingness to reduce price On January 11, Inner Mongolia pharmaceutical purchasing platform also issued the notice on announcing the application of Hunan Dongting Pharmaceutical Co., Ltd and other enterprises to cancel the qualification of drug Internet access Due to the rise of raw materials, production line transformation, environmental pollution and other reasons, 7 pharmaceutical enterprises applied to cancel 14 drug Internet access qualifications In addition, there are also pharmaceutical companies that apply to cancel the Internet connection due to the shortage of APIs For example, on January 28, Shanxi provincial centralized bidding purchase network of medical devices issued the notice of Shanxi Province on publicizing the cancellation of qualification of cefepime hydrochloride for injection in Shanghai Shiguibao Pharmaceutical Co., Ltd of China and the United States in 2019 Shiguibao enterprise proposed that due to the shortage of raw materials, the production of Cefepime for injection (1g and 0.5g) had been stopped, the application for cancellation of network hanging in Shanxi Province had been made, and it was promised to be cancelled nationwide Network hanging and supply.